💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Procter & Gamble Health Limited is an India-based multinational consumer goods company. The Company is focused on manufacturing and marketing of over-the-counter products, vitamins, minerals, and supplements products for a healthy lifestyle. The Company is engaged in the…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
An exceptional, steadily growing business, fairly priced.
Procter & Gamble Health is scored on the pharma / healthcare framework. It keeps a fat 22.9% of every rupee of sales as net profit. Cash broadly tracks reported profit (CFO/PAT 1.03×). Free cash flow is worth about 3.7% of its market value.
Over the last 3 years revenue compounded at 5%/yr and profit at 13%/yr. Net worth has actually shrunk (-5%/yr) — value is not being built. Return on equity is an elite 57.7%. In the latest quarter profit grew 2% versus the prior quarter.
At 39× earnings, the stock sits at the 52nd percentile of its own 4.4-year range — the middle of where it has historically traded. Today's price implies ~12%/yr earnings growth for a decade. The books come through clean — a forensic grade of A, and Altman puts distress risk in the safe zone.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 24.23 | — | — |
| P/B | 13.99 | 4.11 | worse |
| EV/EBITDA | 16.45 | 19.15 | better |
| ROE | 57.72 | — | — |
| ROCE | 78.25 | — | — |
| ROA | 37.44 | — | — |
| Quick Ratio | 1.65 | 4.8 | worse |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Sun Pharmaceutical Industries | 40.6 | 5.0 | 13.8% |
| Divis Laboratories | 93.5 | 16.3 | 15.3% |
| Torrent Pharmaceuticals | 85.9 | 9.8 | 11.4% |
5% CAGR — growing but slowly. Growth is accelerating — latest year outpaced the prior year's rate.
Profit is growing faster than revenue (13% vs 5%) — margin expansion is at work. The latest year saw a +39% swing — check if it's a one-off or structural.
Operating margin has expanded from 25% to 32% — the business is keeping more of each rupee earned.
ROE at 44% — the business earns well above its cost of equity. ROE powered by fat margins — the hallmark of a high-quality franchise with pricing power. Capital efficiency improving — ROE up 13pp across the window.
Profit grew faster than EPS (13% vs 1%) — share dilution is eroding per-share value. 1% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
Operating cash flow has been positive every year — the business generates real cash, not just accounting profit. Financing outflows in consecutive years — balance-sheet discipline through debt repayment or dividends.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue broadly flat QoQ — stable but not accelerating.
How today's P/E compares to the stock's own historical range. Dashed line = the 4.4y median.
Promoter holding at 51.8% — majority control intact.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.